ABBOTT LABORATORIES (ABT)
Abbott Laboratories (NYSE: ABT) is a global healthcare company headquartered in Abbott Park, Illinois. It develops and manufactures medical devices, diagnostic testing systems, nutritional products, and branded generic pharmaceuticals. Its portfolio includes FreeStyle Libre continuous glucose monitoring systems, cardiovascular devices, laboratory diagnostics, and nutrition brands such as Ensure and Similac. Abbott serves patients, healthcare providers, hospitals, laboratories, and consumers in more than 160 countries.
| Ticker | ABT |
|---|
| Company | ABBOTT LABORATORIES |
|---|
| Exchange | NYSE |
|---|
| Headquarters | ABBOTT PARK, IL |
|---|
Income statement — period ending 2026-06-30
| AmortizationOfIntangibleAssets | $658,000 |
|---|
| AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | 11,873 USD/shares |
|---|
| AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | 9,900 USD/shares |
|---|
| CostOfGoodsAndServicesSold | $5,325,000 |
|---|
| CostOfGoodsAndServicesSold | $10,215,000 |
|---|
| CostsAndExpenses | $10,900,000 |
|---|
| CostsAndExpenses | $20,719,000 |
|---|
| EarningsPerShareBasic | 1 USD/shares |
|---|
| EarningsPerShareBasic | 1 USD/shares |
|---|
| EarningsPerShareDiluted | 1 USD/shares |
|---|
| EarningsPerShareDiluted | 1 USD/shares |
|---|
| ForeignCurrencyTransactionGainLossBeforeTax | $4,000 |
|---|
| ForeignCurrencyTransactionGainLossBeforeTax | -$9,000 |
|---|
| Gross Profit (derived) | $7,268,000 |
|---|
| Gross Profit (derived) | $13,542,000 |
|---|
| IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $2,973,000 |
|---|
| IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | $1,524,000 |
|---|
| IncomeTaxExpenseBenefit | $596,000 |
|---|
| IncomeTaxExpenseBenefit | $968,000 |
|---|
| IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | $2,561,000 |
|---|
| IncrementalCommonSharesAttributableToShareBasedPaymentArrangements | $3,576,000 |
|---|
| InterestExpenseNonoperating | $351,000 |
|---|
| InterestExpenseNonoperating | $525,000 |
|---|
| InvestmentIncomeInterest | -$52,000 |
|---|
| InvestmentIncomeInterest | -$158,000 |
|---|
| NetIncomeLoss | $928,000 |
|---|
| OperatingIncomeLoss | $1,693,000 |
|---|
| OperatingIncomeLoss | $3,038,000 |
|---|
| OtherNonoperatingIncomeExpense | -$134,000 |
|---|
| OtherNonoperatingIncomeExpense | -$293,000 |
|---|
| ResearchAndDevelopmentExpense | $892,000 |
|---|
| ResearchAndDevelopmentExpense | $1,659,000 |
|---|
| RevenueFromContractWithCustomerExcludingAssessedTax | $12,593,000 |
|---|
| RevenueFromContractWithCustomerExcludingAssessedTax | $23,757,000 |
|---|
| SellingGeneralAndAdministrativeExpense | $4,025,000 |
|---|
| SellingGeneralAndAdministrativeExpense | $7,765,000 |
|---|
| WeightedAverageNumberOfDilutedSharesOutstanding | $1,742,981,000 |
|---|
| WeightedAverageNumberOfDilutedSharesOutstanding | $1,745,014,000 |
|---|
| WeightedAverageNumberOfSharesOutstandingBasic | $1,740,420,000 |
|---|
| WeightedAverageNumberOfSharesOutstandingBasic | $1,741,438,000 |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro